ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: paper man who wrote (331)	6/8/1998 6:55:00 PM
From: BARRY ALLEN	Read Replies (1) of 4891

Look at the facts paper man! A total of 43 patients with HIV-1 infection, who had never received anti-retroviral therapy, were randomized to receive either Reticulose (21 patients) or placebo (22 patients), at a dosage of two 1ml subcutaneous (SC) injections per day for two weeks, followed by 1ml SC per day every other week for a total of 60 days (total 30 days treatment). There were no toxic effects observed in, or reported by, patients receiving Reticulose. 12 out of 21 still ALIVE after 2 years with improved quality of life!! It was only administered to 21 patients originally! Damn good result! As good as AZT standing alone but without any side effects! I suggest you keep re-reading that article until it sinks in! Sorry.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next